Literature DB >> 28915117

Molecular genetic and clinical delineation of 22 patients with congenital hypogonadotropic hypogonadism.

Kohei Aoyama1, Haruo Mizuno1, Tatsushi Tanaka1, Takao Togawa1, Yutaka Negishi1, Kei Ohashi1, Ikumi Hori1, Masako Izawa1, Takashi Hamajima1, Shinji Saitoh1.   

Abstract

BACKGROUND: Congenital hypogonadotropic hypogonadism (CHH) is classified as Kallmann syndrome (KS) with anosmia/hyposmia or normosmic (n)CHH. Here, we investigated the genetic causes and phenotype-genotype correlations in Japanese patients with CHH.
METHODS: We enrolled 22 Japanese patients with CHH from 21 families (18 patients with KS and 4 with nCHH) and analyzed 27 genes implicated in CHH by next-generation and Sanger sequencing.
RESULTS: We detected 12 potentially pathogenic mutations in 11 families, with three having a mutation in ANOS1 (X-linked recessive); three and four having a mutation in FGFR1 and CHD7, respectively (autosomal dominant); and one having two TACR3 mutations (autosomal recessive). Among four patients with KS carrying a CHD7 mutation, one had perceptive deafness and two had a cleft lip/palate.
CONCLUSIONS: The frequency of CHH genes in the Japanese was compatible with previous reports, except that CHD7 mutations might be more common. Furthermore, partial phenotype-genotype correlations were demonstrated in our cohort.

Entities:  

Keywords:  ANOS1; CHD7; FGFR1; Kallmann syndrome; hypogonadotropic hypogonadism

Mesh:

Substances:

Year:  2017        PMID: 28915117     DOI: 10.1515/jpem-2017-0035

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  8 in total

1.  A novel stopgain mutation c.G992A (p.W331X) in TACR3 gene was identified in nonobstructive azoospermia by targeted next-generation sequencing.

Authors:  Dongfeng Geng; Xiao Yang; Ruixue Wang; Shu Deng; Leilei Li; Xiaonan Hu; Yuting Jiang; Ruizhi Liu
Journal:  J Clin Lab Anal       Date:  2018-11-02       Impact factor: 2.352

2.  Functional Rescue of Inactivating Mutations of the Human Neurokinin 3 Receptor Using Pharmacological Chaperones.

Authors:  Ross C Anderson; Sharika Hanyroup; Yong Bhum Song; Zulfiah Mohamed-Moosa; Iman van den Bout; Alexis C Schwulst; Ursula B Kaiser; Robert P Millar; Claire L Newton
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

3.  High frequency of CHD7 mutations in congenital hypogonadotropic hypogonadism.

Authors:  Catarina Inês Gonçalves; Filipa Marina Patriarca; José Maria Aragüés; Davide Carvalho; Fernando Fonseca; Sofia Martins; Olinda Marques; Bernardo Dias Pereira; José Martinez-de-Oliveira; Manuel Carlos Lemos
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

Review 4.  Dental-craniofacial manifestation and treatment of rare diseases.

Authors:  En Luo; Hanghang Liu; Qiucheng Zhao; Bing Shi; Qianming Chen
Journal:  Int J Oral Sci       Date:  2019-02-20       Impact factor: 6.344

5.  Combined pituitary hormone deficiency in a patient with an FGFR1 missense variant: case report and literature review.

Authors:  Shinichiro Sano; Yohei Masunaga; Fumiko Kato; Yasuko Fujisawa; Hirotomo Saitsu; Tsutomu Ogata
Journal:  Clin Pediatr Endocrinol       Date:  2022-04-23

6.  The Clinical and Genetic Characteristics in Children with Idiopathic Hypogonadotropin Hypogonadism.

Authors:  Qiong Zhou; Wenbin Sheng; Suhong Yang; Chaochun Zou
Journal:  J Oncol       Date:  2022-09-19       Impact factor: 4.501

7.  Identification of KISS1R gene mutations in disorders of non-obstructive azoospermia in the northeast population of China.

Authors:  Dongfeng Geng; Hongguo Zhang; Xiangyin Liu; Jia Fei; Yuting Jiang; Ruizhi Liu; Ruixue Wang; Guirong Zhang
Journal:  J Clin Lab Anal       Date:  2019-12-10       Impact factor: 2.352

Review 8.  Molecular genetic diagnostics of hypogonadotropic hypogonadism: from panel design towards result interpretation in clinical practice.

Authors:  Henriett Butz; Gábor Nyírő; Petra Anna Kurucz; István Likó; Attila Patócs
Journal:  Hum Genet       Date:  2020-03-28       Impact factor: 4.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.